Daratumumab for the treatment of relapsed/refractory AL amyloidosis: experience from the amyloidosis Program of Calgary (APC)

Leuk Lymphoma. 2024 Mar;65(3):403-406. doi: 10.1080/10428194.2023.2290468. Epub 2023 Dec 6.

Authors

Daniel Levin¹, Ellen Lewis¹, Sylvia McCulloch¹, Holly Lee¹, Jason Tay^{1

2}, Peter Duggan^{1

2}, Paola Neri^{1

2}, Nizar Bahlis^{1

2}, Victor H Jimenez-Zepeda^{1

2}

Affiliations

¹ Department of Medical Oncology and Hematology, Tom Baker Cancer Center, Calgary, AB, Canada.
² Charbonneau Cancer Research Institute, Calgary, AB, Canada.

PMID: 38054823
DOI: 10.1080/10428194.2023.2290468

No abstract available

MeSH terms

Amyloidosis*
Antibodies, Monoclonal / adverse effects
Humans
Immunoglobulin Light-chain Amyloidosis* / diagnosis
Immunoglobulin Light-chain Amyloidosis* / drug therapy
Treatment Outcome

Substances

daratumumab
Antibodies, Monoclonal